Kuehne + Nagel and GSK sign long-term global logistics partnership contract
![](/46/pdcnewsitem/03/87/22/kuehne%20%26%20nagel.gif)
Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.
Kuehne + Nagel and GSK have signed an end-to-end global logistics partnership until 2021 that will see Kuehne + Nagel run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.
The contract officially marks the commencement of a relationship which brings significant logistics alignment between the two companies; with Kuehne + Nagel providing skills, expertise and strategic capability to deliver enhanced value across GSK's global supply chain operations.
With numerous suppliers, a large number of manufacturing units and a variety of specific routes to patients and consumers in over one hundred countries; GSK requires a sophisticated and truly global end-to-end logistics solution. Kuehne + Nagel was selected as a partner due to the company's existing track record with GSK, strength in the industry, maturity of Integrated Logistics provision and significant investment strategy in pharmaceuticals and consumer products logistics. In all engagements the cultural fit and complementary approaches of both companies has been evident.
Detlef Trefzger, CEO of Kuehne + Nagel International AG, stated: "We are very excited about this long term collaboration with GSK. Our focus is to leverage existing experience and industry-specific solutions serving the pharmaceutical and consumer sector which will deliver incremental benefits to GSK. Our integrated logistics approach, comprising air, sea, overland services and Logistics Control Centres in four regional hubs will enable GSK's global supply chains to move to the next level of performance."
The new working relationship is a transformational development for both GSK and Kuehne + Nagel in its scale and ambition. It is one of Kuehne + Nagel's biggest customer awards and marks significant progress towards realising both GSK's ambition of a world class supply chain and Kuehne + Nagel's goal to be the leading provider of end-to-end solutions in the pharmaceutical and consumer sectors.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance